# US 2021/0263010 A1 · Ex vivo methods of screening for, and characterizing, cardiac therapeutics using preloaded cardiac tissues

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0263010 A1
- Document ID: US20210263010A1
- Status: Published application
- Kind: A1
- Application number: 17/254,264
- Filed: 2019-06-18
- Published: 2021-08-26
- Earliest claimed: 2018-06-20
- Assignees: NovoHeart Limited
- Applicants: Novoheart Limited
- Inventors: Ronald A. Li; Kevin D. Costa
- Web page: https://patentgrep.com/patent/US20210263010A1

## CPC

- C12N 5/0657: {Cardiomyocytes; Heart cells}
- G01N 33/4833: {of solid biological material, e.g. tissue samples, cell cultures (tissue in vivo A61B5/00; cell suspensions G01N33/48735)}
- C12N 2502/1323: Adult fibroblasts
- C12N 2502/1329: Cardiomyocytes
- C12N 2506/02: from embryonic cells
- C12N 2513/00: 3D culture
- C12N 2527/00: Culture process characterised by the use of mechanical forces, e.g. strain, vibration
- C12N 2529/00: Culture process characterised by the use of electromagnetic stimulation
- C12N 2533/54: Collagen; Gelatin
- C12N 2533/76: Agarose, agar-agar
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

Provided are methods and materials for assaying known and candidate therapeutics for inotropic cardiac effects in one or more in vitro assay formats comprising preloaded cardiac tissues and/or organoids.

## Claims

### Claim 1

A method of assessing the effect of a compound on a cardiomyocyte comprising:
(a) preloading cardiomyocytes of a biocompatible gel apparatus by moving a biocompatible gel support member not fixed in space to stretch the biocompatible gel comprising cardiomyocytes, wherein the biocompatible gel apparatus comprises:
(i) a biocompatible gel comprising a plurality of cardiomyocytes;
(ii) a biocompatible support apparatus for suspending the biocompatible gel, wherein the biocompatible support apparatus comprises at least two support members, wherein a subset of the support members is fixed in space, and wherein the biocompatible gel and biocompatible support apparatus form a cardiac tissue strip comprising cardiomyocytes;
(iii) a motor attached to at least one support member that is not fixed in space for stretching the biocompatible gel in at least one dimension;
(iv) a detection device for detecting movement of the biocompatible gel; and
(v) an electrical power source for applying an electrical pacing stimulus to the biocompatible gel;
(b) administering an effective amount of a compound to the biocompatible gel; and
(c) measuring the response of the biocompatible gel comprising cardiomyocytes to the compound.

### Claim 2 (depends on 1)

The method of claim 1 wherein the response being measured is a positive inotropic response or a negative inotropic response.

### Claim 3 (depends on 1)

The method of claim 1 wherein the compound is a pharmacological agent and the response being measured is a response to the pharmacological agent.

### Claim 4 (depends on 1)

The method of claim 1 wherein the compound is a known therapeutic.

### Claim 5 (depends on 4)

The method of claim 4 wherein the known therapeutic is useful in treating a cardiac disease or disorder.

### Claim 6 (depends on 5)

The method of claim 5 wherein the cardiac disease or disorder is dilated cardiomyopathy, hypertrophic cardiomyopathy, pulmonary atresia, Tetralogy of Fallot, dilated cardiomyopathy with ataxia or heterotaxy syndrome.

### Claim 7 (depends on 4)

The method of claim 4 wherein the known therapeutic is useful in treating a non-cardiac disease or disorder.

### Claim 8 (depends on 7)

The method of claim 7 wherein the non-cardiac disease or disorder is Friedreich's ataxia (FRDA), Kearns-Sayre syndrome, carbohydrate-deficient glycoprotein syndrome type Ia (phosphomannomutase-2 congenital defect of glycosylation Ia or PMM2-CDG-Ia), spinocerebellar ataxia, Wilson disease, Dandy-Walker syndrome, Leigh disease, mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS), myoclonic epilepsy with ragged red fibers (MERRF) or heterotaxy syndrome.

### Claim 9 (depends on 1)

The method of claim 1 wherein the compound is a candidate therapeutic for a cardiac disease or disorder, or for a non-cardiac disease or disorder.

### Claim 10 (depends on 1)

The method of claim 1 wherein the motor induces a change in length of the hydrogel comprising cardiomyocytes of between 1-50% of the length of the preloaded hydrogel comprising cardiomyocytes prior to administration of the compound.

### Claim 11 (depends on 10)

The method of claim 10 wherein the change in length of the hydrogel comprising cardiomyocytes is between 20-30% of the length of the preloaded hydrogel comprising cardiomyocytes prior to administration of the compound.

### Claim 12 (depends on 1)

The method of claim 1 wherein the cardiomyocyte is a healthy cardiomyocyte, the method further comprising a comparison of the effect of the compound on the healthy cardiomyocyte to the effect of the compound on a diseased cardiomyocyte to reveal at least one phenotypic difference between the healthy and diseased cardiomyocytes.

### Claim 13 (depends on 12)

The method of claim 12 wherein the healthy cardiomyocytes and the diseased cardiomyocytes are subjected to the same degree of physiomimetic stretch.

### Claim 14 (depends on 12)

The method of claim 12 wherein the phenotypic difference is a difference in contractile force, contractile rate, or relaxation rate.

### Claim 15 (depends on 14)

The method of claim 14 wherein the diseased cardiomyocytes exhibit a contractile force of less than 20 μN.

### Claim 16 (depends on 14)

The method of claim 14 wherein the diseased cardiomyocytes are from a subject with Friedrich's Ataxia.

### Claim 17 (depends on 14)

The method of claim 14 wherein the phenotypic difference increases as the degree of stretching increases up to optimal length for force production (Lmax).

### Claim 18 (depends on 14)

The method of claim 14 wherein the phenotypic difference is determined at 50% Lmax.

### Claim 19 (depends on 14)

The method of claim 14 wherein the phenotypic difference for contractile force is determined at 80-100% Lmax.

### Claim 20 (depends on 14)

The method of claim 14 wherein the phenotypic difference for contractile rate is determined at 80-100% Lmax.

### Claim 21 (depends on 14)

The method of claim 14 wherein the phenotypic difference for relaxation rate is determined at 90-100% Lmax.

### Claim 22

A method for assaying a response of a cardiac organoid to a compound comprising:
(a) preloading a cardiac organoid by adjusting the hydrostatic pressure to expand the cardiac organoid, wherein the cardiac organoid is housed in at least one organoid module comprising:
(i) at least one organoid module, wherein each organoid module comprises a media inlet, a media outlet, and at least one wall compatible with an external detection device, wherein the cardiac organoid comprises at least one human cell, wherein the cell is a human embryonic stem cell, a human adult stem cell, a human induced pluripotent stem cell, a cell derived from a human tissue, or a progenitor cell of a human tissue, and wherein the cardiac organoid is in fluid communication with a fluid pump or a fluid reservoir comprising an adjustable volume of fluid, wherein the fluid pump or fluid reservoir modulates the pressure within the organoid;
(ii) a mirror arrangement for simultaneous monitoring of any biological development of the cardiac organoid in each of at least two organoid modules; and
(iii) a detection device for observing the monitored biological development of the cardiac organoid in each of at least two organoid modules;
(b) administering the compound to the cardiac organoid; and
(c) detecting a response of the cardiac organoid to the compound.

### Claim 23 (depends on 22)

The method of claim 22 wherein the response is a positive inotropic response or a negative inotropic response.

### Claim 24 (depends on 22)

The method of claim 22 wherein the compound is a pharmacological agent and the response is a response to the pharmacological agent.

### Claim 25 (depends on 22)

The method of claim 22 wherein the compound is a known therapeutic.

### Claim 26 (depends on 25)

The method of claim 25 wherein the known therapeutic is useful in treating a cardiac disease or disorder.

### Claim 27 (depends on 26)

The method of claim 26 wherein the cardiac disease or disorder is dilated cardiomyopathy, hypertrophic cardiomyopathy, pulmonary atresia, Tetralogy of Fallot, dilated cardiomyopathy with ataxia or heterotaxy syndrome.

### Claim 28 (depends on 25)

The method of claim 25 wherein the known therapeutic is useful in treating a non-cardiac disease or disorder having at least one cardiac effect.

### Claim 29 (depends on 28)

The method of claim 28 wherein the non-cardiac disease or disorder is Friedreich's ataxia (FRDA), Kearns-Sayre syndrome, carbohydrate-deficient glycoprotein syndrome type Ia (phosphomannomutase-2 congenital defect of glycosylation Ia or PMM2-CDG-Ia), spinocerebellar ataxia, Wilson disease, Dandy-Walker syndrome, Leigh disease, mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS), or myoclonic epilepsy with ragged red fibers (MERRF).

### Claim 30 (depends on 22)

The method of claim 22 wherein the compound is a candidate therapeutic for a cardiac disease or disorder, or for a non-cardiac disease or disorder.

### Claim 31 (depends on 22)

The method of claim 22 wherein the pressure inside the organoid chamber induces a change in stroke work of between 1-50% of stroke work of the preloaded organoid chamber comprising cardiomyocytes prior to administration of the compound.

### Claim 32 (depends on 31)

The method of claim 31 wherein the change in stroke work is between 20-30% of the preloaded organoid chamber comprising cardiomyocytes prior to administration of the compound.

### Claim 33 (depends on 22)

The method of claim 22 wherein the cardiac organoid is a healthy cardiac organoid, the method further comprising a comparison of the effect of the compound on the healthy cardiac organoid to the effect of the compound on a diseased cardiac organoid to reveal at least one phenotypic difference between the healthy and diseased cardiac organoids.

### Claim 34 (depends on 33)

The method of claim 33 wherein the pressure applied to the healthy cardiac organoid and the diseased cardiac organoid is the same.

### Claim 35 (depends on 33)

The method of claim 33 wherein the phenotypic difference is a difference in contractile force, contractile rate, or relaxation rate.

### Claim 36 (depends on 33)

The method of claim 33 wherein the diseased cardiac organoid exhibits a developed pressure of less than 2 mm H2O.

### Claim 37 (depends on 35)

The method of claim 35 wherein the diseased cardiac organoid is from a subject with Friedrich's Ataxia.

### Claim 38 (depends on 22)

The method of claim 22 wherein the cardiac organoid is electrically paced using 5 volts/cm at a frequency of 1.5 Hz.

### Claim 39 (depends on 22)

The method of claim 22 wherein the stroke work is greater in the presence of the compound than in its absence, at a positive preloading of the cardiac organoid of at least 2.5 mm H2O.

### Claim 40 (depends on 39)

The method of claim 39 wherein the difference in stroke work increases as the degree of preloading increases from 2.5 mm H2O to 7.5 mm H2O.

### Claim 41 (depends on 22)

The method of claim 22 wherein the stroke work is lower in the presence of the compound than in its absence at a positive preloading of the cardiac organoid of at least 2.5 mm H2O.

### Claim 42 (depends on 41)

The method of claim 41 wherein the difference in stroke work increases as the degree of preloading increases from 2.5 mm H2O to 7.5 mm H2O.
